Conditions:   Diabetes Mellitus, Type 2;   Cardiovascular Diseases;   Risk Factors
Interventions:   Drug: Canagliflozin on background standard of care for diabetes;   Drug: Placebo on background standard of care for diabetes
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   George Institute, Sydney, Australia
Recruiting - verified February 2010

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: taspoglutide;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Recruiting - verified March 2010

Conditions:   Influenza A Virus, H1N1 Subtype;   Influenza B Virus;   Influenza, Human;   Influenza, Seasonal
Intervention:   Drug: zanamivir aqueous solution
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: BI 10773;   Drug: BI 10773;   Drug: BI 10773
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010

Condition:   Pulmonary Disease, Chronic Obstructive
Interventions:   Drug: GW642444 Inhalation Powder;   Drug: FF/GW642444 Inhalation Powder
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Macular Degeneration
Interventions:   Device: Epimacular Brachytherapy;   Drug: Ranibizumab
Sponsors:   King's College Hospital NHS Trust;   NeoVista
Recruiting - verified February 2010

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: exenatide once weekly;   Drug: insulin detemir
Sponsors:   Amylin Pharmaceuticals, Inc.;   Eli Lilly and Company
Recruiting - verified December 2009

Condition:   Essential Hypertension
Interventions:   Drug: TAK-491 and chlorthalidone;   Drug: Olmesartan medoxomil-hydrochlorothiazide
Sponsor:   Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2010

Condition:   Juvenile Idiopathic Arthritis
Interventions:   Drug: tocilizumab [RoActemra];   Drug: tocilizumab [RoActemra];   Drug: tocilizumab [RoActemra];   Drug: placebo;   Drug: NSAIDs, corticosteroids, methotrexate
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Pulmonary Disease, Chronic Obstructive
Interventions:   Drug: Tiotropium 18mcg daily;   Drug: Salmeterol 100mcg daily;   Drug: Fluticasone 250mcg daily;   Drug: Fluticasone 125mcg daily;   Drug: Fluticasone 50mcg daily;   Drug: Placebo
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (HOE901);   Drug: Insulin aspart;   Drug: Insulin Glulisine
Sponsor:   Sanofi-Aventis
Recruiting - verified March 2010

Conditions:   Chemotherapy Induced Mucositis;   Mouth Pain
Intervention:   Drug: Buprenorphine
Sponsor:   Mundipharma Research Limited
Recruiting - verified March 2010

Condition:   Bronchiectasis
Interventions:   Drug: Cipro (Ciprofloxacin, BAYQ3939);   Drug: Placebo
Sponsors:   Bayer;   Novartis
Recruiting - verified February 2010

Condition:   Endometrial Cancer
Interventions:   Drug: BN83495;   Drug: Megestrol Acetate (MA)
Sponsor:   Ipsen
Recruiting - verified February 2010

Condition:   Rheumatoid Arthritis
Intervention:   Drug: tocilizumab [RoActemra]
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Alogliptin and metformin;   Drug: Alogliptin and metformin;   Drug: Glipizide and metformin
Sponsor:   Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010

Condition:   Systemic Sclerosis
Intervention:   Drug: treprostinil diethanolamine
Sponsor:   United Therapeutics
Not yet recruiting - verified February 2009

Condition:   Chronic Obstructive Pulmonary Disease
Interventions:   Drug: Indacaterol 150 µg;   Drug: Tiotropium
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified February 2010

Conditions:   Metastatic;   Colorectal Cancer
Interventions:   Drug: Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin);   Drug: Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
Sponsors:   Bayer;   Onyx Pharmaceuticals
Recruiting - verified February 2010

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Apixaban;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke University
Recruiting - verified October 2009

Condition:   Cystic Fibrosis
Interventions:   Drug: Ataluren (PTC124);   Drug: Placebo
Sponsors:   PTC Therapeutics;   Genzyme;   Cystic Fibrosis Foundation
Recruiting - verified March 2010

Conditions:   Atherosclerosis;   Cardiovascular Disease;   Coronary Heart Disease;   CV Risk
Interventions:   Drug: Darapladib;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Drug: bevacizumab [Avastin];   Drug: Oxaliplatin;   Drug: Leucovorin;   Drug: 5-FU;   Drug: 5-FU;   Drug: Leucovorin;   Drug: 5-FU;   Drug: Irinotecan
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Conditions:   Systemic Sclerosis;   Scleroderma
Interventions:   Drug: treprostinil diethanolamine;   Drug: placebo
Sponsor:   United Therapeutics
Recruiting - verified February 2010

Condition:   Idiopathic Pulmonary Fibrosis
Intervention:   Drug: ambrisentan or sugar pill
Sponsor:   Gilead Sciences
Recruiting - verified March 2010

Condition:   Optic Neuropathy, Ischemic
Intervention:  
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified October 2009

Condition:   Rheumatoid Arthritis
Intervention:   Drug: tocilizumab [RoActemra]
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Neuroendocrine Tumors
Intervention:  
Sponsor:   Ipsen
Recruiting - verified February 2010

Condition:   Crohn's Disease
Interventions:   Drug: Laquinimod;   Drug: placebo
Sponsor:   Teva Pharmaceutical Industries
Recruiting - verified March 2010

Conditions:   Diabetic Retinopathy;   Diabetes Complications
Interventions:   Procedure: Laser Treatment;   Drug: PF-04523655 high;   Drug: PF-04523655 middle;   Drug: PF-04523655 low
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Candida;   Candidiasis
Interventions:   Drug: Anidulafungin;   Drug: Fluconazole;   Drug: Voriconazole
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Diabetic Macular Edema
Interventions:   Drug: Choline Fenofibrate;   Drug: Placebo
Sponsor:   Solvay Pharmaceuticals
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Drug: bevacizumab [Avastin];   Drug: Standard chemotherapy
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Infant, Small for Gestational Age
Interventions:   Drug: Genotropin (PN-180,307) Somatropin;   Other: Control-no treatment
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Drug: ZD4054;   Drug: Luteinising hormone-releasing hormone analogue (LHRHa);   Drug: Megace;   Drug: Estradiol;   Drug: Prednisolone;   Drug: Ketoconazole;   Drug: Docetaxel
Sponsor:   AstraZeneca
Recruiting - verified February 2010

Condition:   Venous Thromboembolism
Interventions:   Drug: Xarelto (Rivaroxaban, BAY59-7939);   Drug: Enoxaparin
Sponsors:   Bayer;   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified March 2010

Condition:   Moderate Risk of CVD
Interventions:   Drug: Aspirin (Acetylsalicylic acid, BAYE4465);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified February 2010

Condition:   Breast Cancer
Interventions:   Biological: Trastuzumab;   Drug: Lapatinib
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Lymphoma, B-Cell
Interventions:   Drug: bevacizumab [Avastin];   Drug: R-CHOP;   Drug: Placebo
Sponsors:   Hoffmann-La Roche;   Genentech
Recruiting - verified February 2010

Condition:   Pain, Postoperative
Interventions:   Drug: pregabalin (Lyrica);   Drug: pregabalin (Lyrica);   Drug: matched placebo
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Cytomegalovirus Infections
Interventions:   Drug: Placebo;   Drug: Valganciclovir
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2009

Condition:   Pulmonary Embolism
Interventions:   Drug: Xarelto (Rivaroxaban, BAY59-7939);   Drug: Enoxaparin followed by VKA
Sponsors:   Bayer;   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified March 2010

Conditions:   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Liver Cancer
Interventions:   Drug: capecitabine;   Other: clinical observation;   Procedure: adjuvant therapy
Sponsor:   Southampton University Hospitals NHS Trust
Recruiting - verified March 2008

Condition:   Idiopathic Thrombocytopenic Purpura
Intervention:   Drug: eltrombopag olamine (SB-497115-GR)
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Epilepsy, Partial
Interventions:   Drug: Pregabalin;   Drug: Lamotrigine
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: busulfan;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   University Hospitals, Leicester;   National Cancer Institute (NCI);   Children's Cancer and Leukaemia Group;   Societe Francaise Oncologie Pediatrique;   European Organization for Research and Treatment of Cancer;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria;   Swiss Group for Clinical Cancer Research;   EBMT Solid Tumors Working Party;   Children's Oncology Group
Recruiting - verified March 2010